Biochip Antigens for Chlamydia trachomatis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Chlamydia trachomatis infections are not sufficiently sensitive, standardized, or cost-effective, often resulting in false-positive results and are difficult to interpret, especially in differentiating between Chlamydia trachomatis and Chlamydia pneumoniae infections.
Innovation Solution
The use of individually immobilized recombinant antigens, specifically CT017, CT098, CT318-L1P, CT431, CT456-TARP, CT603-TSAP, and CT664, for selective detection of Chlamydia trachomatis-specific antibodies in samples, employing biochip technology and ELISA assays to achieve high specificity and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used to detect Chlamydia infections, then the detection can be performed, but the sensitivity and specificity are insufficient leading to false-positive results
Solution Approach 1:
The invention segments the detection process by using multiple specific antigens (CT017, CT098, CT318-L1P, CT431, CT456-TARP, CT603-TSAP, CT664) instead of a single antigen or non-specific antigen mixture. This segmentation allows for more precise detection of C. trachomatis-specific antibodies and reduces cross-reactivity with C. pneumoniae, thereby improving both sensitivity and specificity while reducing false-positive results
Solution Approach 2:
The invention applies local quality by selecting and using specific immunodominant antigens that are uniquely expressed by C. trachomatis or expressed at significantly higher levels compared to C. pneumoniae. Each antigen has specific epitopes that confer high specificity for C. trachomatis detection, allowing the detection system to focus on locally optimized recognition sites rather than relying on general Chlamydia antigens that cross-react between species
2Measurement precision
If species-specific detection methods are developed, then diagnostic accuracy improves, but the method complexity and difficulty of interpretation increase
Solution Approach 1:
The invention creates a universal detection system using a panel of seven specific antigens that can simultaneously detect and differentiate between C. trachomatis and C. pneumoniae infections. The same antigen panel and ELISA methodology can be used for both species differentiation and for distinguishing acute from chronic infections, providing multi-functional capability without increasing operational complexity. The system serves multiple diagnostic purposes with a single standardized protocol
Solution Approach 2:
The invention simplifies interpretation by establishing quantitative parameter thresholds for diagnosis. Specific antibody concentration cutoff values are defined for each antigen, and diagnostic criteria are based on meeting specific parameter thresholds (e.g., antibody levels above certain concentrations indicate active infection). This transforms complex immunological responses into simple yes/no diagnostic decisions based on clear numerical parameters
3Measurement precision
If highly sensitive detection methods are implemented, then chronic infections can be detected, but the cost-effectiveness and ease of routine use decrease
Solution Approach 1:
The invention uses recombinant antigens produced through cost-effective molecular biology techniques (PCR amplification, expression in E. coli or other expression systems). These antigens can be produced cheaply and used in disposable ELISA test kits. The antigens are stable and can be stored at standard refrigeration temperatures, eliminating the need for expensive specialized equipment or complex sample processing. Each ELISA plate can be used as a disposable unit, reducing contamination risks and eliminating the need for expensive centralized laboratory infrastructure
Solution Approach 2:
The invention replaces complex mechanical or molecular diagnostic systems with a simple ELISA-based immunological assay. Instead of using sophisticated molecular biology techniques requiring specialized equipment, the patent uses antibody-antigen binding reactions that can be performed with standard ELISA equipment available in most clinical laboratories. This substitution maintains high sensitivity for detecting chronic infections while dramatically reducing costs and simplifying routine use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise species differentiation and distinguishes between active and chronic infections, reducing cross-reactivity and improving diagnostic accuracy, making it suitable for routine laboratory use and cost-effective.
Implementation Method 1
The antigens being selected from the group consisting of: CT017, CT098, CT318-L1P, CT431, CT456-TARP, CT603-TSAP and CT664, and additionally preferably also from fragments and partial sequences of the above antigens or from essentially the same antigens used to detect antibodies in samples
Data Source
AI summary
The present invention relates to a method for the selective identification of Chlamydia trachomatis infections, wherein the antigenes CT017, CT098, CT318-L1 P, CT431, CT456- TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates a selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae. The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis-specific antigenes for the identification of antibodies. The biochip with the antigenes according to the invention is suitable for multiparameter identification methods in particular.